Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maribavir - Takeda

Drug Profile

Maribavir - Takeda

Alternative Names: 1263W94; Benzimidavir; Camvia; GW 1263; GW 1263W94; SHP-620; TAK 620; VP41263

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Takeda; ViroPharma
  • Class Antivirals; Benzimidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action Ganciclovir kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 04 Jan 2018 Maribavir - Shire receives Breakthrough Therapy status for Cytomegalovirus infections in USA
  • 29 Apr 2017 Adverse events data from a phase II trial in Cytomegalovirus infections presented at the 2017 American Transplant Congress (ATC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top